X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SHASUN PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SHASUN PHARMA ORCHID PHARMA LTD/
SHASUN PHARMA
 
P/E (TTM) x -0.2 123.9 - View Chart
P/BV x 0.1 8.5 1.5% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ORCHID PHARMA LTD   SHASUN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SHASUN PHARMA
Mar-14
ORCHID PHARMA LTD/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs19494 205.9%   
Low Rs3546 76.8%   
Sales per share (Unadj.) Rs276.5214.2 129.1%  
Earnings per share (Unadj.) Rs-79.25.3 -1,484.5%  
Cash flow per share (Unadj.) Rs-43.515.8 -274.7%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %01.4 0.0%  
Book value per share (Unadj.) Rs53.953.3 101.1%  
Shares outstanding (eoy) m70.4556.62 124.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.40.3 126.9%   
Avg P/E ratio x-1.413.1 -11.0%  
P/CF ratio (eoy) x-2.64.4 -59.6%  
Price / Book Value ratio x2.11.3 162.0%  
Dividend payout %018.7 0.0%   
Avg Mkt Cap Rs m8,0673,958 203.8%   
No. of employees `0002.8NA-   
Total wages/salary Rs m2,5272,164 116.8%   
Avg. sales/employee Rs Th6,956.1NM-  
Avg. wages/employee Rs Th902.5NM-  
Avg. net profit/employee Rs Th-1,993.0NM-  
INCOME DATA
Net Sales Rs m19,47712,127 160.6%  
Other income Rs m407229 177.5%   
Total revenues Rs m19,88412,356 160.9%   
Gross profit Rs m1,1031,009 109.3%  
Depreciation Rs m2,519594 424.4%   
Interest Rs m5,227415 1,259.2%   
Profit before tax Rs m-6,236230 -2,714.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125-73 172.2%   
Profit after tax Rs m-5,580302 -1,847.0%  
Gross profit margin %5.78.3 68.0%  
Effective tax rate %2.0-31.7 -6.3%   
Net profit margin %-28.72.5 -1,150.0%  
BALANCE SHEET DATA
Current assets Rs m11,0146,884 160.0%   
Current liabilities Rs m32,0608,456 379.1%   
Net working cap to sales %-108.1-13.0 833.8%  
Current ratio x0.30.8 42.2%  
Inventory Days Days9562 154.0%  
Debtors Days Days34108 31.2%  
Net fixed assets Rs m29,4404,970 592.3%   
Share capital Rs m705113 621.8%   
"Free" reserves Rs m2,0432,875 71.0%   
Net worth Rs m3,8003,020 125.8%   
Long term debt Rs m9,0181,817 496.2%   
Total assets Rs m46,51013,347 348.5%  
Interest coverage x-0.21.6 -12.4%   
Debt to equity ratio x2.40.6 394.4%  
Sales to assets ratio x0.40.9 46.1%   
Return on assets %-0.85.4 -14.1%  
Return on equity %-146.910.0 -1,468.1%  
Return on capital %-3.713.3 -28.0%  
Exports to sales %37.946.4 81.7%   
Imports to sales %22.614.2 158.8%   
Exports (fob) Rs m7,3785,622 131.2%   
Imports (cif) Rs m4,4061,728 255.0%   
Fx inflow Rs m7,5135,843 128.6%   
Fx outflow Rs m5,6492,173 259.9%   
Net fx Rs m1,8653,669 50.8%   
CASH FLOW
From Operations Rs m1,682398 423.0%  
From Investments Rs m-9,860-1,635 603.1%  
From Financial Activity Rs m6,6441,309 507.7%  
Net Cashflow Rs m-1,53571 -2,155.9%  

Share Holding

Indian Promoters % 32.3 39.2 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 3.6 127.8%  
FIIs % 3.3 17.6 18.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 39.6 139.6%  
Shareholders   84,811 20,750 408.7%  
Pledged promoter(s) holding % 54.9 12.3 446.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   AUROBINDO PHARMA  WYETH LTD  ABBOTT INDIA  FULFORD INDIA  DR. REDDYS LAB  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex below 38,000-Mark, HUL, L&T Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets extended their decline for the 4th day as markets witnessed selling pressure during closing hours.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 23, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS